14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
HOLX vs DGX
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HOLX vs DGX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HOLX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)
HOLX Overall Winner
6-Pillar Tally: HOLX 3 – 3 DGX
Matrix Metrics: HOLX 6 – 4 DGX
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Quest Diagnostics Inc. (DGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas DGX carries 50.5/100 (HOLD) at $258.28 (21.6x Forward P/E, 14.9% operating margin).
HOLX
NASDAQ
Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Market Cap
$16.9B
TTM Revenue
$4.13B
Forward P/E
20.1x
Beta / 30D Vol
0.08β · 3% Vol
Unified Composite Score
64.2 / 100
BUY
Tech 75.0
Fund 61.0
Flow 54.0
Mom 49.2
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
DGX
NYSE
Quest Diagnostics Inc.
Services-Medical Laboratories
Market Cap
$28.5B
TTM Revenue
$11.8B
Forward P/E
21.6x
Beta / 30D Vol
-0.04β · 20% Vol
Unified Composite Score
50.5 / 100
HOLD
Tech 31.0
Fund 47.0
Flow 56.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $254.57 · SMA50: $243.73
6-Pillar Scorecard Institutional Category Breakdown (HOLX 3 – 3 DGX)
Columns: Metric · HOLX · DGX
1. Valuation Multiples
DGX
Forward P/E
20.1x
21.6x
Trailing P/E
31.4x
25.8x
PEG Ratio
1.66x
1.68x
EV / Revenue
4.1x
2.9x
2. Growth & Scale
DGX
Revenue Growth (YoY)
+2.5%
+10.0%
Earnings Growth (YoY)
-9.2%
+28.7%
TTM Revenue (USD)
$4.13B
$11.8B
Market Cap
$16.9B
$28.5B
3. Profitability & Quality
HOLX
Gross Margin
60.4%
33.2%
Operating Margin
23.0%
14.9%
Net Profit Margin
13.2%
9.5%
Return on Equity (ROE)
10.9%
15.3%
4. Balance Sheet & Cash Flow
HOLX
Cash Generation (TTM)
$1.35B EBITDA
$1.38B
Cash Flow Margin
32.7% EBITDA Mgn
11.6%
Net Cash / Leverage
$23.51 Book/Sh · 10.9% ROE
$5.49B Net Debt (0.82x D/E)
Dividend Yield
None (0.00%)
1.30%
5. Options & Positioning
DGX
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
6.3% (3rd %ile)
29.7% (16th %ile)
Put/Call OI Skew
6.20x (Put-Skewed)
0.14x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
HOLX
OpEx & R&D Intensity
37.4% of Rev ($1.54B)
18.3% of Rev ($2.17B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: HOLX (6) vs DGX (4)
Institutional Metric
HOLX
DGX
Criterion
Row Edge
Market Capitalization
Scale
$16.9B
$28.5B
Larger Scale
DGX
Trailing P/E Ratio
Valuation
31.4x
25.8x
Lower Multiple
DGX
Forward P/E Ratio
Valuation
20.1x
21.6x
Lower Multiple
HOLX
Revenue Growth (YoY)
Growth
+2.5%
+10.0%
Higher Growth
DGX
Operating Margin (TTM)
Profitability
23.0%
14.9%
Higher Margin
HOLX
Net Profit Margin
Profitability
13.2%
9.5%
Higher Margin
HOLX
Return on Equity (ROE)
Capital Efficiency
10.9%
15.3%
Higher ROE
DGX
52-Week Range Position
Momentum
100% ($52–$76)
95% ($171–$263)
Stronger Trend
HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol
-0.04β · 20% Vol
Lower Realized Risk
HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY)
50.5 / 100 (HOLD)
Higher Composite
HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B
$11.8B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4%
33.2%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev
1.68x PEG · 2.9x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE)
$1.38B ($5.49B Net Debt (0.82x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
HOLX +2.8 pp
HOLX:
+0.34%
·
DGX:
-2.46%
3M Horizon
DGX +12.54 pp
HOLX:
+1.94%
·
DGX:
+14.48%
6M Horizon
DGX +4.51 pp
HOLX:
+2.48%
·
DGX:
+6.99%
1Y Horizon
DGX +4.51 pp
HOLX:
+2.48%
·
DGX:
+6.99%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs DGX. Trailing 12-month operating profitability (HOLX 23.0% vs DGX 14.9%) and valuation multiples (HOLX 20.1x vs DGX 21.6x Forward P/E) are benchmarked directly in Pillar 4 below.
HOLX ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $4.13B
Gross Margin 60.4%
Op. Margin 23.0%
ROE / Fwd P/E 10.9% · 20.1x
DGX ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $11.8B
Gross Margin 33.2%
Op. Margin 14.9%
ROE / Fwd P/E 15.3% · 21.6x
HOLX
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
6.3%
IV Percentile
3rd %ile
Put/Call OI Skew
6.20x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
DGX
CONSOLIDATION
75d in phase · OBV ACCUMULATION
Current IV
29.7%
IV Percentile
16th %ile
Put/Call OI Skew
0.14x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
5-DAY BULLISH SWING
Liq B
Dec 18 $260 / $280 Bull Call Spread
Buy 1x $260C · Sell 1x $280C · 28d
Net Entry
$510 Debit
T+5d @ +5% Move
+$418 (+82%)
Max Risk / Buffer
$510 Capped
5d Edge & Liquidity
1.2x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME
Liq B
Dec 18 $250 / $240 Bull Put Spread
Sell 1x $250P · Buy 1x $240P · 28d
Net Entry
$320 Credit
Max Credit / Yield
+$320 (+47.1% RoM)
Max Risk / Buffer
-5.0% Cushion ($680 Mgn)
5d Edge & Liquidity
69% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD
Liq C
Dec 18 $260 / $250 Bear Put Spread
Buy 1x $260P · Sell 1x $250P · 28d
Net Entry
$268 Debit
T+5d @ -5% Drop
+$259 (+97%)
Max Risk / Buffer
$268 Capped
5d Edge & Liquidity
1.4x R:R · Liq C
Simulate 5-Day Payoff →
HOLX Moat Profile
Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment
37.4% of Rev ($1.54B)
90D Engineering Disclosures
0 Published
DGX Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $28.5B market capitalization and 14.9% operating margin.
OpEx & R&D Reinvestment
18.3% of Rev ($2.17B)
90D Engineering Disclosures
0 Published
Investor FAQ HOLX vs DGX Key Questions & Quantitative Answers
Is HOLX or DGX a better stock to buy right now?
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Quest Diagnostics Inc. (DGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas DGX carries 50.5/100 (HOLD) at $258.28 (21.6x Forward P/E, 14.9% operating margin). Technically, HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure) and DGX sits in a Markup phase (RSI 60.8, CONSOLIDATION options structure).
Does HOLX or DGX have stronger revenue and earnings growth?
DGX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with DGX at +10.0% YoY revenue growth and +28.7% YoY earnings growth on $11.8B TTM revenue (33.2% gross margin, 14.9% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $11.8B for DGX. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 18.3% of Rev ($2.17B) (0 disclosures) for DGX.
Is HOLX or DGX cheaper on valuation?
DGX screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas DGX trades at 21.6x Forward P/E, 25.8x Trailing P/E, 1.68x PEG, and 2.9x EV/Revenue (11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus DGX (15.3% ROE) capital efficiency.
How is options market volatility positioned on HOLX vs DGX?
In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, DGX carries 29.7% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 20% Vol realized risk).
Hologic Inc (HOLX) Research Suite
Quest Diagnostics Inc. (DGX) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.